diabetes mellitus changed due to the introduction on the European market of the first GLP-1 receptor agonist, exenatide, and the first inhibitor of DPP-4, sitagliptin. These drugs ... throughout the potentiation of…
Pancreatic alpha cells secrete glucagon-like peptide 1 (GLP-1), the production of which is enhanced by the chemokine stromal derived factor 1 (SDF-1). Since SDF-1, like GLP ... further enhancement by the combination…
cell therapy. We examine the effect of gut hormones including glucagon like peptide- 1(GLP-1) and obestatin in generation of IPCs in-vitro from WJ-MSCs in comparison ... mesenchymal lineages. WJ-MSCs under proliferation…
current treatment options of Diabetes mellitus is increasing Glucagon-like peptide-1 (GLP-1) activity. GLP1, a gastrointestinal peptide with incretin effect, has a significant role in glucose homeostasis…
Recent advances in pharmacological obesity management have delivered highly effective treatments. Dual GIP/GLP-1 receptor agonists like tirzepatide show substantial weight loss and cardiometabolic benefits. GLP-1…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly utilized as a primary treatment option for patients with type 2 diabetes (T2D) due to their efficacy in glycemic ... glycemic targets. This article…
bisecting GlcNAc were increased in AD models, and glucagon-like peptide-1 (GLP-1) receptor agonists could downregulate aberrant expression of GnT-III through the Akt/GSK-3Ã?²/Ã?²-catenin ... function might be damaged by…
mini review we revised limited studies addressing the potential use of agents mediating through GLP-1 in PCOS. We reported that short-term intervention with long acting GLP-1 analogue ... behavior in obese PCOS…
NASH) and type 2 diabetes mellitus, (T2DM) demonstrates how when glucagon-like peptide-1, (GLP-1) is synchronously released into the splanchnic blood during intestinal glucose absorption, it stimulates superior…
Dulaglutide is a novel continuous-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of Type 2 diabetes. It consists of two modified ‘GLP-1’ moieties
noninsulin therapies has been clearly defined. Salutary metabolic effects of glucagon like peptide (GLP)-1 and glucosedependent insulinotropic peptide or gastric inhibitory peptide have been difficult to capture, since…
diabetes, incretin-based therapies have been an established treatment since their introduction in 2006. GLP‑1 receptor agonists as an injectable therapy and DPP‑4 inhibitors as oral antidiabetic agents ... action on…
Liraglutide is an analog of the human peptide hormone GLP-1 and a member of the GLP-1 receptor agonists class, which has recently been developed for treatment of Type
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that potentiate insulin secretion in a glucose-dependent manner. Selective GLP-1 and GIP secretagogue…
search for new markers with additional information of the arteriosclerotic burden in PCOS. GLP-1 analogues, originally developed for the treatment of diabetes, induce weight loss also in non-diabetic ... people. We…
recovery, preclinical development, clinical trials and manufacturing. Indeed, preclinical development through Good Laboratory Practices (GLP) have an important role in clinical trials to achieve Good Clinical Practice…
glucagon-like peptide-1 (GLP-1) receptor is a member of the family B G proteincoupled receptors (GPCRs) that contains many important drug targets. Its natural ligand, GLP ... solution of three-dimensional structures of…
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that potentiate insulin secretion in a glucose-dependent manner. Selective GLP-1 and GIP secretagogue…
Glucagon-Like peptide-1 (GLP-1) is a 30 or 31 amino corrosive long peptide chemical getting from the tissue-explicit posttranslational handling of the proglucagon peptide. It is delivered ... core of the lone plot in…
loss. It primarily achieves this through substantial changes in appetite hormones like ghrelin and GLP-1, reducing hunger and increasing satiety [1]. The surgery also impacts the gut microbiota, neural
systems, detailing hormone signaling pathways in metabolism, development, and disease. It covers thyroid hormones, GLP-1, glucocorticoid receptors, FGF21, and adiponectin in metabolic regulation and diabetes. Further…
This compilation reviews Type 2 Diabetes, detailing advancements in pharmacological treatments, including GLP-1 receptor agonists and SGLT2 inhibitors, noting their efficacy in glycemic control and cardiovascular…
life. This article reviews current pharmacologic therapies, including metformin, insulin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and other emerging agents. We discuss the mechanisms…
noninsulin diabetes medications, such as oral antihyperglycemics, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and SGLT-2 inhibitors, along with their indications, clinical benefits, and challenges in the…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.